What's in ACTAVIS LABS UT INC's pipeline?

ACTAVIS LABS UT INC has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ACTAVIS LABS UT INC's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/actavis-labs-ut-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

ACTAVIS LABS UT INC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACTAVIS LABS UT INC pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Condylox	podophyllotoxin	marketed	podophyllotoxin	Glucocorticoid receptor	Other	1990-01-01
Butalbital, Aspirin And Caffeine	BUTALBITAL	marketed	Barbiturate [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2	Neuroscience	1976-01-01

Therapeutic area mix

Neuroscience · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for ACTAVIS LABS UT INC:

Cite this brief

Drug Landscape (2026). ACTAVIS LABS UT INC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/actavis-labs-ut-inc. Accessed 2026-06-10.